摘要:
The present invention relates to a compound represented by the general formula Ila or IIb
or a solvate or salt thereof, wherein
is selected from
and
is selected from
Y1, Y2, Y3, Y4, Y5, Y6, Y7 and Y8 are independently selected from CR3 and N, with the proviso that at least one of Y1, Y2, Y3, Y4, Y5, Y6, Y7 and Y8 is N and with the proviso that in the formulae la or Ib, at least one of Y1, Y3, Y4, and Y6 is N; R1 is independently selected from hydrogen, C1-4 alkyl and -(CH2)-O-P(=O)(OR)(OR), wherein C1-4 alkyl can be optionally substituted by one or more halogen; R2 is independently selected from hydrogen, halogen, and C1-4 alkyl, wherein C1-4 alkyl can be optionally substituted by one or more halogen; R is hydrogen or a cation; R3 is hydrogen; R4 and R5 are independently selected from H and C1-4 alkyl, wherein C1-4 alkyl can be optionally substituted by one or more halogen or wherein R4 and R5 together with the nitrogen atom to which they are bound form a piperazinyl ring which is substituted by one or more R6; and R6 is independently selected from halogen, C1-4 alkyl, OH and C1-4 alkoxy, wherein C1-4 alkyl and C1-4 alkoxy can be optionally substituted by one or more halogen; and Hal is halogen.
摘要:
The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.